Benchmark Co. reiterated their hold rating on shares of Amedisys Inc (NASDAQ:AMED) in a research report released on Thursday morning, MarketBeat reports.

Other research analysts have also issued research reports about the stock. Mizuho reissued a buy rating and issued a $65.00 price objective (up previously from $55.00) on shares of Amedisys in a research note on Wednesday. BidaskClub lowered shares of Amedisys from a strong-buy rating to a buy rating in a research note on Wednesday, July 12th. Oppenheimer Holdings, Inc. reissued a buy rating and issued a $60.00 price objective on shares of Amedisys in a research note on Friday, September 15th. Bank of America Corporation assumed coverage on shares of Amedisys in a research note on Monday, August 21st. They issued a neutral rating and a $55.00 price objective for the company. Finally, Royal Bank Of Canada reissued a hold rating on shares of Amedisys in a research note on Monday, October 23rd. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Amedisys currently has a consensus rating of Hold and a consensus price target of $61.00.

Amedisys (NASDAQ AMED) traded down $0.14 during midday trading on Thursday, hitting $56.25. 310,900 shares of the stock traded hands, compared to its average volume of 485,523. The company has a current ratio of 1.33, a quick ratio of 1.21 and a debt-to-equity ratio of 0.16. Amedisys has a twelve month low of $38.00 and a twelve month high of $65.91. The stock has a market capitalization of $1,908.96, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 1.37 and a beta of 0.68.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business had revenue of $380.20 million during the quarter, compared to analyst estimates of $384.59 million. During the same quarter last year, the firm posted $0.36 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. analysts forecast that Amedisys will post 2.22 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/amedisys-amed-hold-rating-reiterated-at-benchmark-co/1697899.html.

Large investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. raised its holdings in Amedisys by 23.9% in the second quarter. UBS Asset Management Americas Inc. now owns 14,572 shares of the health services provider’s stock valued at $915,000 after acquiring an additional 2,812 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Amedisys by 1.5% in the second quarter. Victory Capital Management Inc. now owns 702,239 shares of the health services provider’s stock valued at $44,108,000 after acquiring an additional 10,080 shares in the last quarter. Vanguard Group Inc. raised its holdings in Amedisys by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock valued at $121,067,000 after acquiring an additional 63,238 shares in the last quarter. Castleark Management LLC acquired a new stake in Amedisys in the second quarter valued at approximately $3,674,000. Finally, Geode Capital Management LLC raised its holdings in Amedisys by 3.2% during the first quarter. Geode Capital Management LLC now owns 231,953 shares of the health services provider’s stock worth $11,850,000 after purchasing an additional 7,279 shares in the last quarter. 96.36% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.